This grant from the Department of Defense aims to provide funding for advanced translational studies and large-scale projects focused on making breakthroughs in breast cancer research. The research projects at Funding Level 3 should have potential for near-term clinical investigation, while Funding Level 4 projects are expected to transform clinical management and/or prevention of breast cancer. The grant encourages collaborations between investigators through the Partnering PI Option, where two PIs each receive a separate award. Applications for Funding Level 4 projects require an invited oral presentation to the BCRP Integration Panel. Deadline for submission is August 15, 2014.
Opportunity ID: 253180
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-BCRP-BREAKTHROUGH34 |
| Funding Opportunity Title: | DoD Breast Cancer Breakthrough Award Levels 3 and 4 |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 28, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 15, 2014 |
| Current Closing Date for Applications: | Aug 15, 2014 |
| Archive Date: | Sep 14, 2014 |
| Estimated Total Program Funding: | $40,000,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. Funding Levels 1 and 2 are available under a different Program Announcement (W81XWH-14-BCRP-BREAKTHROUGH12). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply. Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects. Note: An invited oral presentation to the BCRP Integration Panel (IP) is a requirement for application review of Funding Level 4 projects, as described in Section II.C., Application Submission Content and Forms. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, called the Initiating PI and the Partnering PI, each of whom will each receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:Email: help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 253180 Full Announcement-1 -> bcrp_fy14 btal34 pa_gg2.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00194534 | Mar 28, 2014 | Aug 15, 2014 | View |
Package 1
Mandatory forms
253180 RR_SF424_2_0-2.0.pdf
253180 RR_Budget_1_3-1.3.pdf
253180 PerformanceSite_2_0-2.0.pdf
Optional forms
253180 RR_KeyPersonExpanded_2_0-2.0.pdf
253180 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
